05.14.2020 - Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months and 86%...
05.14.2020 - ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Final analysis of the Phase 3 SPARTAN study presented during ASCO Virtual Scientific Program suggests 14-month improvement in median overall survival
Supplier Quality Expectations
In order to be considered as a potential supplier or to continue supplying Companies within the Johnson & Johnson Family of Companies, suppliers must meet a set of minimum expectations.